Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 5:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 707 matching trials from the live ClinicalTrials.gov search.
Filters: "mild cognitive impairment" Condition: Alzheimer's Disease Clear all
Completed Phase 2 Interventional Results available

A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)

NCT05619692
View directory record Official record
Conditions
Mild Cognitive Impairment, Mild Dementia, Alzheimer's Disease
Interventions
SAGE-718, SAGE-718-matching Placebo
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
37
States / cities
Gilbert, Arizona • Phoenix, Arizona • Lafayette, California + 34 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 10, 2026, 5:26 PM EDT
Completed Not applicable Interventional

Coaching for Cognition in Alzheimer's (COCOA)

NCT03424200
View directory record Official record
Conditions
Alzheimer Disease, Cognitive Impairment
Interventions
Routine care, Coaching plus routine care
Behavioral · Other
Lead sponsor
Hoag Memorial Hospital Presbyterian
Other
Eligibility
50 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Sep 26, 2022 · Synced Oct 10, 2026, 5:26 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Detecting an MCI and Amyloid Digital Neuro Signature(DNS) Using Altoida's Multimodal Digital Biomarkers.

NCT06223438
View directory record Official record
Conditions
Alzheimer Disease, MCI
Interventions
Not listed
Lead sponsor
Altoida
Industry
Eligibility
50 Years and older
Enrollment
614 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Oct 10, 2026, 5:26 PM EDT
Completed Not applicable Interventional

Metabolic Cerebral Imaging in Incipient Dementia (MCI-ID)

NCT00329706
View directory record Official record
Conditions
Dementia
Interventions
FDG-PET brain scan
Procedure
Lead sponsor
University of California, Los Angeles
Other
Eligibility
65 Years and older
Enrollment
710 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
9
States / cities
Phoenix, Arizona • Los Angeles, California • Santa Monica, California + 5 more
Source: ClinicalTrials.gov public record
Updated May 2, 2017 · Synced Oct 10, 2026, 5:26 PM EDT
Withdrawn Phase 2 Interventional

Improving Beta-2 Adrenergic Signaling in Alzheimer's Disease

NCT02500784
View directory record Official record
Conditions
Alzheimer's Disease, Cognitive Dysfunction
Interventions
Formoterol A, Formoterol B (placebo)
Drug · Other
Lead sponsor
Palo Alto Veterans Institute for Research
Other
Eligibility
50 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 10, 2026, 5:26 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

The A-LIST WMM Insights Series

NCT04466722
View directory record Official record
Conditions
Alzheimer Disease, Dementia, Mild Cognitive Impairment
Interventions
Not listed
Lead sponsor
UsAgainstAlzheimer's
Other
Eligibility
18 Years to 100 Years
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 15, 2022 · Synced Oct 10, 2026, 5:26 PM EDT
Recruiting Phase 2 Interventional

Biomarker-based Trial of NPC-1 for Alzheimer's Pathology

NCT07236190
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment (MCI), Subjective Cognitive Decline (SCD)
Interventions
natural product combination-1 (NPC1)
Combination Product
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
55 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 10, 2026, 5:26 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Evaluation and Follow-up of Individuals With Memory Disorder

NCT00001480
View directory record Official record
Conditions
Alzheimer's Disease, Dementia, Healthy, Memory Disorder
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 90 Years
Enrollment
750 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1995 – 2007
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 10, 2026, 5:26 PM EDT
Completed Phase 2 Interventional Results available

Trial of Rifaximin in Probable Alzheimer's Disease

NCT03856359
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Rifaximin 550 milligrams (MG)
Drug
Lead sponsor
Duke University
Other
Eligibility
55 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 17, 2021 · Synced Oct 10, 2026, 5:26 PM EDT
Completed Not applicable Interventional Results available

Self-Administered Interactive Exercise Program (Tele-Exergame)

NCT07072962
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI), Mild Alzheimer Disease, Memory Deficits
Interventions
home-based self-administered interactive exercise
Device
Lead sponsor
Baylor College of Medicine
Other
Eligibility
50 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 3, 2025 · Synced Oct 10, 2026, 5:26 PM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

Visualizing Brain Proteinopathies Using [F-18]Flornaptitril-PET in the Prediction of Clinical Progression of Mild Cognitive Impairment With Either Suspected Chronic Traumatic Encephalopathy or Alzheimer's Disease

NCT06254469
View directory record Official record
Conditions
Alzheimer Disease, Chronic Traumatic Encephalopathy
Interventions
[F-18]Flornaptitril
Drug
Lead sponsor
CereMark Pharma, LLC
Industry
Eligibility
45 Years and older
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Oct 10, 2026, 5:26 PM EDT
Completed Phase 3 Interventional Results available

Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease

NCT04994483
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Simufilam, Placebo
Drug
Lead sponsor
Cassava Sciences, Inc.
Industry
Eligibility
50 Years to 87 Years
Enrollment
804 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
74
States / cities
Chandler, Arizona • Gilbert, Arizona • Phoenix, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 10, 2026, 5:26 PM EDT
Completed Phase 3 Interventional Results available

Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With an Acetylcholinesterase Inhibitor

NCT02006654
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Placebo, Idalopirdine
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
50 Years and older
Enrollment
734 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
26
States / cities
Mesa, Arizona • Bellflower, California • Costa Mesa, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Oct 10, 2026, 5:26 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Metformin in Alzheimer's Dementia Prevention

NCT04098666
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Placebo oral tablet, extended release metformin
Drug
Lead sponsor
Columbia University
Other
Eligibility
55 Years to 90 Years
Enrollment
326 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
22
States / cities
Irvine, California • Palo Alto, California • Washington D.C., District of Columbia + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 10, 2026, 5:26 PM EDT
Completed Not applicable Interventional Results available

Study of the Effects of Cerefolin NAC on Inflammation Blood Markers in Older Individuals With Memory Complaints

NCT00597376
View directory record Official record
Conditions
Subjective Memory Loss in Older Persons
Interventions
Cerefolin NAC (a medical food), Cerefolin NAC placebo
Other
Lead sponsor
Rush University Medical Center
Other
Eligibility
60 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 23, 2013 · Synced Oct 10, 2026, 5:26 PM EDT
Completed Not applicable Interventional Results available

FitMi AD Home Therapy for Individuals With MCI or Mild Dementia Due to Alzheimer's Disease

NCT05504811
View directory record Official record
Conditions
Cognitive Dysfunction, Dementia, Mild
Interventions
FitMi AD, Conventional exercise program
Device · Other
Lead sponsor
Flint Rehabilitation Devices, LLC
Industry
Eligibility
50 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Downey, California
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 10, 2026, 5:26 PM EDT
Terminated Phase 1 Interventional

Study of the Pharmacokinetics and Pharmacodynamics of POSIPHEN® in Subjects With Amnestic Mild Cognitive Impairment

NCT01072812
View directory record Official record
Conditions
Alzheimer's Disease, Amnestic Mild Cognitive Impairment
Interventions
Posiphen® tartrate capsules
Drug
Lead sponsor
Annovis Bio Inc.
Industry
Eligibility
55 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 22, 2015 · Synced Oct 10, 2026, 5:26 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

COcoa Supplement and Multivitamin Outcomes Study for the Mind

NCT03035201
View directory record Official record
Conditions
Cognitive Impairment, Dementia, Aging
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
65 Years and older
Enrollment
2,262 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Oct 10, 2026, 5:26 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Alzheimer's Disease Neuroimaging Initiative Grand Opportunity

NCT01078636
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer's Disease
Interventions
Not listed
Lead sponsor
Alzheimer's Disease Cooperative Study (ADCS)
Other
Eligibility
55 Years to 90 Years
Enrollment
342 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
50
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2014 · Synced Oct 10, 2026, 5:26 PM EDT
Completed Phase 2 Interventional

Impact of Grape Consumption on Brain Metabolism and Neuropsychological Performance Over 1 Year

NCT03361410
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Grape Powder, Placebo Powder
Dietary Supplement
Lead sponsor
University of California, Los Angeles
Other
Eligibility
65 Years to 85 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 10, 2026, 5:26 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Practice Effects and Amyloid Imaging Using 18F-PIB or Flutemetamol PET and FDG-PET

NCT01202994
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
18F-Flutemetamol
Drug
Lead sponsor
University of Utah
Other
Eligibility
65 Years and older
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Oct 10, 2026, 5:26 PM EDT
Not yet recruiting Phase 2 Interventional

Restoring Vascular and Insulin Function To Augment Anti-Amyloid Therapy in Alzheimer's Disease

NCT07756294
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Empagliflozin, Insulin, Insulin Placebo, Empagliflozin Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
55 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 10, 2026, 5:26 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Study To Assess The Feasibility Of Indivi Mobile Application In Monitoring Cognitive Performance In Aging Population

NCT07174869
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI), Mild Alzheimer Disease
Interventions
Not listed
Lead sponsor
Indivi AG
Industry
Eligibility
50 Years to 90 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 10, 2026, 5:26 PM EDT
Completed Phase 2 Interventional Results available

A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease

NCT05063539
View directory record Official record
Conditions
Alzheimer Disease
Interventions
LY3372689, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
60 Years to 85 Years
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
35
States / cities
Canoga Park, California • Fresno, California • Irvine, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 10, 2026, 5:26 PM EDT